Dr. C. Michael Gibson of Harvard Medical School observes a notable trend among his cardiology peers at heart disease meetings: many are adopting new obesity medications from Eli Lilly and Novo Nordisk, resulting in significant weight loss. Dr. Robert Califf, former FDA chief, notes he hardly recognizes the thinness of his colleagues compared to before. Although no studies document the exact percentage of physicians taking these drugs, Califf believes the aggressive adoption by doctors signifies their effectiveness, reminiscent of the early embrace of statins to manage high cholesterol.
When Dr. C. Michael Gibson, a cardiologist at Harvard Medical School, observes his colleagues, there is a palpable shift: they are increasingly turning to new obesity drugs.
Dr. Robert Califf notes the notable transformation among his fellow cardiologists, emphasizing that so many have achieved significant weight loss thanks to these effective medications.
Collection
[
|
...
]